Table 1 Treatment Courses of the 6 Patients Receiving HTx for primary cardiac sarcomas in Our Institution
From: Survival after heart transplantation for non-metastatic primary cardiac sarcoma
Age/Sex | Histology (Grade) | Tumor Sites | Operations before HTX, Interval (mo) | Multimodal Therapies | Tumor Relapse (mo) | Outcome Survival (mo) |
|---|---|---|---|---|---|---|
63/M | Synovial Sarcoma (G3) | LV, RV | Partial resection, 7 | NT(pre-), XRT to metastasis | Lung (1) | D, 5 |
48/M | Angiosarcoma (G3) | RA, RV | Biopsy, 3 | IAP(post-op) | Liver, Chest (4), | D, 5 |
27/F | Angiosarcoma (G3) | RA, RV | Biopsy, 2 | IAP(post-op) | Lung (12) | D, 15 |
49/F | Undifferentiated Pleomorphic Sarcoma (G3) | RA, LA, LV | Partial resection, 5 | Re-HTx at 36mo | PV (33), Liver, PV (40) | D, 43 |
49/F | Undifferentiated Pleomorphic Sarcoma (G2) | LA, LV | Partial resection, 9 | No | - | Da, 18 |
61/M | Myxoid Liposarcoma, (G2) | RV | Partial resection, 3 | No | - | Alive, 93 |